An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases
- 1 April 2006
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Vaccines
- Vol. 5 (2), 189-198
- https://doi.org/10.1586/14760584.5.2.189
Abstract
This article provides a perspective on vaccine development for neglected tropical diseases in the nonprofit setting, with particular emphasis on recombinant protein vaccines. The Human Hookworm Vaccine Initiative is discussed as a model product development public-private partnership, and the major challenges are covered that accompany antigen selection, gene cloning, fermentation and purification process development, assay development, vaccine formulation and testing and clinical evaluation for those developing vaccines, especially against neglected tropical diseases, in the nonprofit sector. Throughout this perspective, special emphasis is placed on the growing promise that product development public-private partnerships hold for developing vaccines for the world's poorest people.Keywords
This publication has 16 references indexed in Scilit:
- Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and MalariaPLoS Medicine, 2006
- Public-private partnership: from there to hereTransactions of the Royal Society of Tropical Medicine and Hygiene, 2005
- The Neglected Tropical Diseases: The Ancient Afflictions of Stigma and Poverty and the Prospects for their Control and EliminationAdvances in experimental medicine and biology, 2005
- “Rapid-Impact Interventions”: How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the PoorPLoS Medicine, 2005
- Expression of the Necator americanus hookworm larval antigen Na-ASP-2 in Pichia pastoris and purification of the recombinant protein for use in human clinical trialsVaccine, 2005
- Health Innovation Networks to Help Developing Countries Address Neglected DiseasesScience, 2005
- A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvantVaccine, 2005
- Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulationsVaccine, 2005
- Hookworm: “The Great Infection of Mankind”PLoS Medicine, 2005
- Vaccines as instruments of foreign policyEMBO Reports, 2001